Search results
Results from the WOW.Com Content Network
Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...
Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus. It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells." [1] [2]
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...
A new treatment is being trialled for the autoimmune condition
Belimumab is primarily used in people with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]
Efavaleukin alfa is an experimental drug that works as an interleukin-2 "mutein Fc fusion protein that preferentially binds the high-affinity IL-2 receptor alpha chain to selectively promote Treg expansion". [1] It is developed to treat systemic lupus erythematosus (SLE). [2] [3] [4]
President Trump rolled back a Biden administration executive order aimed at lowering prescription drug prices, including an effort to make more generic drugs available to Medicare patients for ...
Ruplizumab (trade name Antova) is a humanized monoclonal antibody intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis. A study showed that the drug was associated with life-threatening thromboembolisms, [1] while another study only found thrombocytopenia. [2]